Abstract
Oxidation injury has been claimed as one of the key factors in the development of coronary heart disease and chronic heart failure [1,2]. The isoprostane 8-epi-PGF22α is gaining increasing interest as reliable marker of in-vivo oxidation injury [3]. As it causes among others coronary vasoconstriction [4] its pathophysiological role may become even more important. We therefore assessed the isoprostane 8-epi-PGF2α in arteries, veins, heart valves and myocardial tissue immunochemically as well as by immunohistochemistry. Furthermore, 8-epi-PGF2α was determined in plasma and urine of patients with CHD compared to patients with dilated and ischemic CMP.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call